A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 256
- 试验地点
- 1
- 主要终点
- Rate of Next-Generation Sequencing (NGS) testing by arm
研究概览
简要总结
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
详细描述
Next-generation sequencing is recommended by national guidelines in metastatic prostate cancer to inform prognosis, treatment decisions, and eligibility for clinical trials. However, rates are low nationally and around 50-60% at Johns Hopkins. Analysis found that older patients and patients who are not married are less likely to have testing performed. The goals and objectives of this proposed clinical trial are to improve NGS testing rates at Johns Hopkins using a multidisciplinary approach to improve the care of patients living with metastatic prostate cancer and reduce disparities. The hypothesis is that this initiative, which targets two barriers (provider-level and patient-level), will lead to higher rates of NGS ordering at Johns Hopkins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •men diagnosed with metastatic prostate cancer
- •seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
排除标准
- •- Patients who have already had NGS testing performed.
研究组 & 干预措施
Provider nudge and patient education at time of enrollment
The provider level component (implemented for all patients) will be a "nudge" to physicians to order testing via a single email documenting their NGS testing rate relative to the Johns Hopkins top performer and, for those not in the top 20%, a link to the most recent American Society of Clinical Oncology (ASCO) guidelines recommending testing. In addition, there will be a patient component that is a one-page handout of educational material about NGS testing to be sent after their initial visit via email or mail.
干预措施: Provider-level and patient-level (Other)
Provider component and patient education at end of study
The provider level component (implemented for all patients) will be a "nudge" to physicians to order testing via a single email documenting their NGS testing rate relative to the Johns Hopkins top performer and, for those not in the top 20%, a link to the most recent ASCO guidelines recommending testing. The patient educational material will be provided by email or mail (if no email on file) to those who randomized to this arm.
干预措施: Provider-level and patient education at end of study (Other)
结局指标
主要结局
Rate of Next-Generation Sequencing (NGS) testing by arm
时间窗: 1 year
次要结局
- Percentage of patients with sociodemographic and clinical characteristics who have had NGS testing compared to those without NGS testing during the study period.(1 year)